Background: Chronic obstructive pulmonary disease (COPD) is a slowly progressive condition characterized by poorly reversible airflow limitation that is associated with an abnormal inflammatory response of the lung. It has been shown that there is a seroepidemiological association of Helicobacter pylori (Hp) infection with many inflammatory conditions. Objective: In this study, we aimed to investigate seroprevalence in Hp patients with COPD and to determine whether there is an association between Hp infection and COPD. Methods: Forty-nine voluntary patients with COPD and 50 healthy control subjects of similar age and sex were included in the study. Hp-specific IgG was measured with a commercially available kit from venous blood samples. Results: Serum levels of Hp-specific IgG and Hp IgG seropositivity were significantly higher in the patients with COPD than in the control subjects (p < 0.001 and p = 0.006, respectively). In addition, when the patients with COPD were grouped according to Hp IgG seropositivity, forced expiratory volume in 1 s (FEV1) values were lower in the seropositive patients compared to seronegative patients, and Hp serum IgG levels were correlated with FEV1 values, which indicate the severity of COPD, in the COPD group (r = –0.306, p = 0.032). Conclusion: The results suggest that there is an association between Hp infection and COPD, and Hp IgG levels are correlated with the severity of COPD.

Keywords:
Chronic obstructive pulmonary disease, Helicobacter pylori, Inflammation, Seroprevalence
1.
Tsang KW, Lam WK, Chan KN, Hu W, Wu A, Kwok E, Zheng L, Wong BC, Lam SK: Helicobacter pylori sero-prevalence in asthma. Respir Med 2000;94:756–759.
2.
Kelley J: Cytokines of the lung. Am Rev Respir Dis 1990;141:765–788.
3.
Eller J, Lapa E, Silva JR, Poulter LW, Lode H, Cole PJ: Cells and cytokines in chronic bronchial infection. Ann NY Acad Sci 1994;725:331–345.
4.
Dinarello CA: Interleukin-1 and the pathogenesis of the acute phase response. N Engl J Med 1984;311:1413–1418
5.
Whincup PH, Mendall MA, Perry IJ, Strachan DP, Walker M: Prospective relations between Helicobacter pylori infection, coronary heart disease and stroke in middle aged men. Heart 1996;75:568–572.
6.
Roussos A, Philippou N, Gourgoulianis KI: Helicobacter pylori infection and respiratory diseases: a review. World J Gastroenterol 2003;9:5–8.
7.
Tsang KW, Lam S, Lam W, Karlberg J, Wong BC, Hu WH, Yew W, Ip MS: High seroprevalence of Helicobacter pylori in active bronchiectasis. Am J Respir Crit Care Med 1998;158:1047–1051.
8.
Gocyk W, Nikliski T, Olechnowicz H, Duda A, Bielanski W, Konturek P, Konturek S: Helicobacter pylori, gastrin and cyclooxygenase-2 in lung cancer. Med Sci Monit 2000;6:1085–1092.
9.
Casselli M, Zaffoni E, Ruina M, Sartori S, Trevisani L, Ciaccia A, Alvisi V, Fabbri L, Papi A: Helicobacter pylori and chronic bronchitis. Scand J Gastroenterol 1999;34:828–830.
10.
Beeh KM, Beier J, Ernst M, Kornmann O, Buhl R: Platinum-based, leukocyte-depleting chemotherapy does not alter induced sputum markers of neutrophilic inflammation in COPD patients with unresectable non-small cell lung cancer. Respiration 2003;70:166–171.
11.
Roussos A, Philippou N, Krietsepi V, Anastasakou E, Alepopoulou D, Koursarakos P, Iliopoulos I, Gourgoulianis K: Helicobacter pylori seroprevalence in patients with chronic obstructive pulmonary disease. Respir Med 2005;99:279–284.
12.
National Heart, Lung, and Blood Institute: Global Initiative for Chronic Obstructive Lung Disease (GOLD): Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Bethesda, National Institutes of Health, 2004, pp 1–112.
13.
Philippou N, Koursarakos P, Anastasakou E, Krietsepi V, Mavrea S, Roussos A, Alepopoulou D, Iliopoulos I: Helicobacter pylori seroprevalence in patients with lung cancer. World J Gastroenterol 2004;10:3342–3344.
14.
Nijevitch AA, Loguinovskaya VV, Tyrtyshnaya LV, Sataev VU, Ogorodnikova IN, Nuriakhmetova AN: Helicobacter pylori infection and reflux esophagitis in children with chronic asthma. Clin Gastroenterol 2004;38:14–18.
15.
Filippou N, Roussos A, Tsimboukas F, Tsimogianni A, Anastasakou E, Mavrea S: Helicobacter pylori seroprevalence in patients with pulmonary tuberculosis. J Clin Gastroenterol 2002;34:189–190.
16.
Roussos A, Tsimpoukas F, Anastasakou E, Alepopoulou D, Paizis I, Philippou N: Helicobacter pylori seroprevalence in patients with chronic bronchitis. J Gastroenterol 2002;37:332–335.
17.
Graham KS, Graham DY: Contemporary Diagnosis and Management of H. pylori-Associated Gastrointestinal Diseases. Newton, Handbooks in Health Care, 2002, pp 87–100.
18.
Sanaka M, Kuyuma Y, Iwasaki M, Hanada Y, Tsuchiya A, Haida T, Hirama S, Yamaoka S, Yamanaka M: No difference in seroprevalences of Helicobacter pylori infection between patients with pulmonary tuberculosis and those without. J Clin Gastroenterol 1998;27:331–334.
19.
Sanaka M, Kuyuma Y, Yamanaka M: Iwasaki M: Decrease of serum concentrations of Helicobacter pylori IgG antibodies during antituberculosis therapy: the possible eradication by rifampicin and streptomycin. Am J Gastroenterol 1999;94:1983–1984.
20.
Sugiyama T, Nishikawa K, Komatsu Y, Ishizuka J, Mizushima T, Kumagai A, Kato M, Saito N, Takeda H, Asaka M, Freston JW: Attributable risk of H. pylori in peptic ulcer disease: does declining prevalence of infection in general population explain increasing frequency of non-H. pylori ulcers? Dig Dis Sci 2001;46:307–310.
21.
Gomez FP, Rodriguez–Roisin R: Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines for chronic obstructive pulmonary disease. Curr Opin Pulm Med 2002;8:81–86.
22.
Graham DY, Malaty HM, Evans DJ, Klein PD, Adam E: Epidemiology of Helicobacter pylori in an asymptomatic population in the United States: effects of age, race, and socioeconomic status. Gastroenterology 1991;100:1495–1501.
23.
Parasher G, Eastwood GL: Smoking and peptic ulcer in the Helicobacter pylori era. Eur J Gastroenterol Hepatol 2000;12:843–853.
24.
Brenner H, Rothenbacher D, Bode G, Adler G: Relation of smoking and alcohol and coffee consumption to active Helicobacter pylori infection: cross-sectional study. BMJ 1997;315:1489–1492.
25.
Ogihara A, Kikuchi S, Hasigawa A, Kurosawa M, Miki K, Kaneko E, Mizukoshi H: Relationship between Helicobacter pylori infection and smoking and drinking habits. J Gastroenterol Hepatol 2000;15:271–276.
26.
Sidebotham RL, Batten JJ, Karim QN, Spencer J, Baron JH: Breakdown of gastric mucus in presence of Helicobacter pylori. J Clin Pathol 1991;44:52–57.
27.
Tsang KW, Hu W, Lam WK, Ip M, Lam SK: A preliminary study of gastro-oesophageal reflux in bronchiectasis. Am J Respir Crit Care Med 1997;155:A107.
28.
Rebora A, Drago F, Picciotto A: Helicobacter pylori in patients with rosacea. Am J Gastroenterol 1994;89:1603–1604.
29.
De Luis DA, Varela C, de la Calle H, Canton R, de Argila CM, San Roman AL, Boixeda D: Helicobacter pylori infection is markedly increased in patients with autoimmune atrophic thyroiditis. J Clin Gastroenterol 1998;26:259–263.
30.
Wedi B, Wagner S, Werfel T, Manns MP, Kapp A: Prevalence of Helicobacter pylori-associated gastritis in chronic urticaria. Int Arch Allergy Immunol 1998;116:288–294.
31.
Reinauer S, Megahed M, Goerz G, Ruzicka T, Borchard F, Susanto F, Reinauer H: Schönlein-Henoch purpura associated with Helicobacter pylori infection. J Am Acad Dermatol 1995;33:876–879.
32.
Palange P, Forte S, Felli A, Galassetti P: Nutritional state and exercise tolerance in patients with COPD. Chest 1995;107:1206–1212.
33.
Fedorova TA, Spirina LIu, Chernekhovskaia NE, Kanareitseva TD, Sotnikova TI, Zhidkova NV, Anchukova EL: The stomach and duodenum condition in patients with chronic obstructive lung diseases. Klin Med (Mosk) 2003;81:31–33.
34.
O’Connor HJ: Helicobacter pylori and gastro-oesophageal reflux disease: clinical implications and management. Aliment Pharmacol Ther 1999;13:117–127.
35.
Labenz J, Malfertheiner P: Helicobacter pylori in gastro-oesophageal reflux disease: causal agent, independent or protective factor? 1997;41:277–280.
36.
Peters FTM, Kleibeuker JH, Postma DS: Gastric asthma: a pathophysiological entity? Scand J Gastroenterol 1998;33(suppl 225):19–23.
37.
Kiljander TO, Salomaa ER, Hietanen EK, Ovaska J, Helenius H, Liippo K: Gastroesophageal reflux and bronchial responsiveness: correlation and the effect of fundoplication. Respiration 2002;69:434–439.
38.
Bagnato GF, Gulli S, Giacobbe O, De Pasquale R, Purello D’Ambrosio F: Bronchial hyperresponsiveness in subjects with gastroesophageal reflux. Respiration 2000;67:507–509.
© 2005 S. Karger AG, Basel
2005
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.